A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy-Reference-Cited by-同舟云学术

A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy

Published:2019-11-15 Issue:3 Volume:38 Page:866-873
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Sohn Byeong Seok,Jeong Jae Ho,Ahn Jin-Hee,Jung Kyung Hae,Kim Jeong Eun,Sohn Joo Hyuk,Koh Su-Jin,Seo Jae Hong,Lee Keun Seok,Kim Sung-Bae^ORCID

Funder

Kyowa Hakko Kirin

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-019-00863-8.pdf

Reference29 articles.

1. Eiermann W, Pienkowski T, Crown J et al (2011) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29:3877–3884. https://doi.org/10.1200/jco.2010.28.5437

2. Kuderer NM, Dale DC, Crawford JLyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158–3167. https://doi.org/10.1200/jco.2006.08.8823

3. Molineux G (2003) Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 23(8 Pt 2):3s–8s. https://doi.org/10.1592/phco.23.9.3S.32886

4. Crawford J (2003) Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 30(4 Suppl 13):24–30. https://doi.org/10.1016/S0093-7754(03)00314-2

5. Molineux G (2004) The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 10:1235–1244. https://doi.org/10.2174/1381612043452613

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the Optimal Regimen: A Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Long-Acting Granulocyte Colony-Stimulating Factors in Patients with Breast Cancer;Cancers;2023-07-19

2. Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma;Supportive Care in Cancer;2021-05-14